Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin ( TECOS )
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims: To report baseline characteristics and cardiovascular ( CV ) risk management by region, age, sex and CV event type for 14 724 participants in the T rial E valuating C ardiovascular O utcomes with S itagliptin ( TECOS ), a randomized, double‐blind, placebo‐controlled trial exploring whether sitagliptin added to usual type 2 diabetes ( T2DM ) care affects time to first event in the composite endpoint of CV death, non‐fatal myocardial infarction ( MI ), non‐fatal stroke or unstable angina hospitalization. Methods: TECOS enrolled patients aged ≥50 years, with T2DM and CV disease from 38 countries in five regions: N orth A merica, E astern E urope, W estern E urope, A sia P acific and L atin A merica. Participants had a glycated haemoglobin concentration of 6.5–8.0% (48–64 mmol/mol) and were receiving oral and/or insulin‐based antihyperglycaemic therapy. Analysis of variance or logistic regression was used to compare regional CV risk factors and treatments, referenced to N orth A merica. Results: Patients had a mean [1 standard deviation (SD)] age of 66 (8) years, a median (interquartile range) diabetes duration of 9.4 (4.9, 15.3) years, and a mean (SD) body mass index 30.2 (5.7) kg/m 2 . Compared with N orth A merica, blood pressure and lipids were higher in all regions. Statin use was lowest in L atin A merica (68%) and E astern E urope (70%) and aspirin use was lower compared with N orth A merica in all regions except A sia P acific. Achievement of treatment targets did not differ by age group or insulin usage, but men and participants with previous MI were more likely than women or those with previous stroke or peripheral arterial disease to reach most treatment goals. Conclusion: The CV risk factors of participants in TECOS are reasonably controlled, but differences in CV risk management according to region, sex and history of disease exist. This diversity will enhance the generalizability of the trial results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“Two other recently reported DPP-4 CV outcomes trials, the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial (EXAMINE, NCT00968708) [27] and the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction trial (SAVOR-T…”
ResultExplaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“Two other recently reported DPP-4 CV outcomes trials, the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial (EXAMINE, NCT00968708) [27] and the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction trial (SAVOR-T…”
ResultMosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s055 · Cited by 1,062
Yusuf, S., Islam, S., Chow, C. K., Rangarajan, S., Dagenais, G., Diaz, R., Gupta, R., Kelishadi, R., Iqbal, R., Avezum, A., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61215-4 · Cited by 964
Peripheral arterial disease in people with diabetes
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3333 · Cited by 953
National Study of Physician Awareness and Adherence to Cardiovascular Disease Prevention Guidelines
Mosca, L., Linfante, A. H., Benjamin, E. J., Berra, K., Hayes, S. N., Walsh, B. W., Fabunmi, R. P., Kwan, J., Mills, T., & Simpson, S. L. (2005) · Circulation · doi:10.1161/01.cir.0000154568.43333.82 · Cited by 757
Cited by
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Self-citationMcGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0103 · Cited by 217
Self-citationClemens, K. K., Woodward, M., Neal, B., & Zinman, B. (2020) · Diabetes Care · doi:10.2337/dc19-2257 · Cited by 70
Ueno, H., Tsuchimochi, W., Wang, H.-W., Yamashita, E., Tsubouchi, C., Nagamine, K., Sakoda, H., & Nakazato, M. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0113-3 · Cited by 38
“77% after 1 year of treatment [3], and randomized trials to evaluate their cardiovascular safety are in progress [4].”
BackgroundPetrie (2016) · doi:10.1097/hjh.0000000000000890 · Cited by 20
Metadata
- Authors
- Bethel, M. A., Green, J. B., Milton, J., Tajar, A., Engel, S. S., Califf, R. M., Holman, R. R., & on behalf of the TECOS Executive Committee
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-02-13
- Volume
- 17
- Issue
- 4
- Pages
- 395-402
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2081225788
- Cited by
- 46
- References
- 10
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.